Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their ratings and price targets for several health care stocks. Citigroup and Argus Research analysts maintain a Buy rating on Eli Lilly (LLY) with increased price targets, indicating potential upside. Wells Fargo downgraded Johnson & Johnson (JNJ) to Equal-Weight, while UBS upgraded it to Buy, both with new price targets. Morgan Stanley and Raymond James analysts provided mixed views on Abbott Laboratories (ABT) with slight adjustments to price targets. Baird and Citigroup analysts maintain positive ratings on Thermo Fisher Scientific (TMO) with significant price target increases. Recent news includes Eli Lilly's SURMOUNT-4 study results, JNJ's asset purchase agreement for XLRP treatment, Abbott's dividend raise, and Thermo Fisher's senior notes offering.
December 28, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbott Laboratories' stock ratings by Morgan Stanley and Raymond James show minimal price target changes, with a recent dividend increase from 51 to 55 cents per share.
The minor price target changes and dividend increase suggest a stable outlook for Abbott Laboratories without significant short-term movement.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Johnson & Johnson received mixed ratings with Wells Fargo downgrading to Equal-Weight and UBS upgrading to Buy, alongside an asset purchase agreement for XLRP treatment.
The conflicting analyst ratings create uncertainty, but the asset purchase agreement for XLRP treatment could provide a positive outlook.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Eli Lilly received Buy ratings from Citigroup and Argus Research with increased price targets, suggesting a 16% and 7% upside respectively, backed by positive study results for Zepbound.
The increased price targets and positive study results for Zepbound indicate a strong potential for stock growth, supported by analysts' high accuracy rates.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Thermo Fisher Scientific maintains Outperform and Buy ratings from Baird and Citigroup, with substantial price target increases and a recent $2.5 billion senior notes offering.
The strong analyst ratings and significant price target increases, coupled with the recent senior notes offering, suggest potential for stock growth.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 85